By Kimberly Chin

 

Becton, Dickinson and Co. (BDX) lowered its adjusted earnings quarter for the year due to recent regulatory and market pressures related to its paclitaxel-coated devices

Becton Dickinson now expects 2019 adjusted earnings between $11.65 and $11.75, down from its previous guidance of $12.05 and $12.15 a share.

In March, the Food and Drug Administration issued a letter warning consumers against using paclitaxel-coated products in their treatment of peripheral arterial disease. Their preliminary study found that subjects treated with paclitazel-coated devices wereabout 50% more at risk of mortality than devices without the coating.

Shares of the medical device and technology company fell 3.2% in premarket trading.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

(END) Dow Jones Newswires

May 09, 2019 06:55 ET (10:55 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Becton Dickinson Charts.
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Becton Dickinson Charts.